CZ253395A3 - Method of controlled activation and degradation of factor vii during purification process - Google Patents

Method of controlled activation and degradation of factor vii during purification process Download PDF

Info

Publication number
CZ253395A3
CZ253395A3 CZ952533A CZ253395A CZ253395A3 CZ 253395 A3 CZ253395 A3 CZ 253395A3 CZ 952533 A CZ952533 A CZ 952533A CZ 253395 A CZ253395 A CZ 253395A CZ 253395 A3 CZ253395 A3 CZ 253395A3
Authority
CZ
Czechia
Prior art keywords
fvii
buffer
nacl
activation
degradation
Prior art date
Application number
CZ952533A
Other languages
Czech (cs)
English (en)
Inventor
Tony Jorgensen
Anders H Pedersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CZ253395A3 publication Critical patent/CZ253395A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CZ952533A 1993-03-31 1994-03-24 Method of controlled activation and degradation of factor vii during purification process CZ253395A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93382A DK38293D0 (da) 1993-03-31 1993-03-31 Fremstilling af proteiner

Publications (1)

Publication Number Publication Date
CZ253395A3 true CZ253395A3 (en) 1996-01-17

Family

ID=8092871

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ952533A CZ253395A3 (en) 1993-03-31 1994-03-24 Method of controlled activation and degradation of factor vii during purification process

Country Status (16)

Country Link
US (1) US5700914A (enExample)
EP (1) EP0691984A1 (enExample)
JP (1) JPH08508264A (enExample)
CN (1) CN1039231C (enExample)
AU (1) AU677309B2 (enExample)
CA (1) CA2159313A1 (enExample)
CZ (1) CZ253395A3 (enExample)
DK (1) DK38293D0 (enExample)
FI (1) FI954649A7 (enExample)
HU (1) HUT72712A (enExample)
IL (1) IL109164A0 (enExample)
NO (1) NO953883L (enExample)
PL (1) PL310887A1 (enExample)
TW (1) TW278079B (enExample)
WO (1) WO1994022905A1 (enExample)
ZA (1) ZA941956B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
JP4469933B2 (ja) † 1998-05-06 2010-06-02 ジェネンテック， インコーポレイテッド イオン交換クロマトグラフィによるタンパク質精製
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
DK2283856T3 (da) 2002-06-21 2017-11-20 Novo Nordisk Healthcare Ag Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider
RU2364626C2 (ru) * 2003-03-18 2009-08-20 Ново Нордиск Хелт Кэр Аг Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
BRPI0416950B8 (pt) 2003-12-01 2021-05-25 Novo Nordisk Healthcare Ag métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida.
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
MX2007007356A (es) * 2004-12-23 2007-08-14 Novo Nordisk Healthcare Ag Reduccion del contenido de contaminantes proteinicos en composiciones que comprenden una proteina dependiente de la vitamina k de interes.
PT1841863E (pt) * 2005-01-14 2010-10-25 Bayer Healthcare Llc Método para a purificação de factor vii
US20070129298A1 (en) * 2005-07-22 2007-06-07 Maxygen Holdings, Ltd. In-solution activation of factor vii
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ES2779992T3 (es) * 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
US10285915B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
ES2906118T3 (es) 2016-12-22 2022-04-13 Km Biologics Co Ltd Método cromatográfico para recolectar factor VII de coagulación sanguínea con alto rendimiento

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins

Also Published As

Publication number Publication date
CN1121723A (zh) 1996-05-01
FI954649A0 (fi) 1995-09-29
NO953883D0 (no) 1995-09-29
NO953883L (no) 1995-11-28
HU9502846D0 (en) 1995-12-28
EP0691984A1 (en) 1996-01-17
CN1039231C (zh) 1998-07-22
HUT72712A (en) 1996-05-28
DK38293D0 (da) 1993-03-31
IL109164A0 (en) 1994-06-24
AU677309B2 (en) 1997-04-17
TW278079B (enExample) 1996-06-11
PL310887A1 (en) 1996-01-08
CA2159313A1 (en) 1994-10-13
WO1994022905A1 (en) 1994-10-13
FI954649L (fi) 1995-09-29
FI954649A7 (fi) 1995-09-29
AU6423994A (en) 1994-10-24
JPH08508264A (ja) 1996-09-03
ZA941956B (en) 1994-09-30
US5700914A (en) 1997-12-23

Similar Documents

Publication Publication Date Title
CZ253395A3 (en) Method of controlled activation and degradation of factor vii during purification process
AU740753C (en) Improved methods for processing activated protein C
Wasley et al. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway.
Stenflo Structure and function of protein C
US20080214462A1 (en) FIX-Mutant Proteins for Hemophilia B Treatment
Josic et al. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C
AU2008209986A1 (en) FVIII-independent FIX-mutant proteins for hemophilia A treatment
PL191778B1 (pl) Analog czynnika X Δ , rekombinowany kwas nukleinowy, wektor, komórka, kompozycje i ich zastosowania oraz sposób wytwarzania kompozycji
US6958322B1 (en) Factor X analog with an improved ability to be activated
RU2167936C2 (ru) Способ минимизации деградации активированного протеина с (варианты), стабилизированная композиция активированного протеина с
US5510248A (en) Stable recombinant meizothrombin-like polypeptides
AU769144B2 (en) Improved methods for processing activated protein C
AU4409399A (en) Human protein c polypeptide
CZ373799A3 (cs) Zlepšené způsoby zpracování aktivovaného proteinu C
Hung Structural-functional Studies of the Non-enzymatic Domains of Prothrombin
Carter Structural-Functional Relationships in the Human Thrombin A-Chain
Su Localization of ligand-binding exosites in the catalytic domain of FXIa and determination of the roles of calcium and the heavy chain of FXIa in fix activation by FXIa
EP1557463A1 (en) Improved methods for processing activated protein C
Boskovic Studies of prothrombinase-catalyzed activation of bovine prothrombin.
SK124699A3 (en) Activated vitamin k-dependent blood factor and method for the production thereof
HK1219285A1 (en) Purification method for vitamin k dependent proteins by anion exchange chromatography
HK1219285B (en) Purification method for vitamin k dependent proteins by anion exchange chromatography